What Reisziekte Treats: Main Uses and Benefits

The medication Reisziekte (Cyclizine) is generally considered relevant across therapeutic domains where acute sickness and balance disturbances may create noticeable physiological strain. It is applied across areas where short-term symptomatic assistance is needed to control distressing manifestations of nausea and vertigo. Its uses are specific and therapeutically focused.

Therapeutic Focus and Key Benefits

The medication's primary therapeutic role is to help with the prevention and symptomatic relief of kinetosis (motion sickness), and is also applied in addressing sickness linked to vestibular disorders (like Ménière's disease), postoperative nausea and vomiting (PONV), and emetic effects from necessary opioid analgesics or radiotherapy. Its function is to help address symptom clusters that may become intense or disruptive, specifically nausea, vomiting, and dizziness. The use of this medication helps support patients during difficult episodes, contributing to easing the overall symptom load during periods of heightened symptoms.

---

Quick Fact: Therapeutic Support

Quick Fact: Therapeutic support for Symptoms that interfere with daily functioning (Nausea, Vomiting, Dizziness).

Regulatory References

1. UK Medicines and Healthcare products Regulatory Agency

The official regulatory profile for Reisziekte (Cyclizine) establishes clear rules for its use based strictly on age, pre-existing conditions, and physiological status.

Absolute Exclusions (Contraindications)

The medicine is strictly contraindicated and must not be used by patients with a known hypersensitivity to cyclizine or its excipients, or in cases of acute alcohol intoxication. Furthermore, use is prohibited for patients with the severe metabolic disorder Porphyria. Specific tablet formulations are also restricted for individuals with certain rare hereditary metabolic issues like galactose intolerance.

Restricted Use and Special Caution

Regulatory documents require the medicine be used with caution in patients who have certain comorbidities where anticholinergic effects are a concern. These include glaucoma, urinary retention, and obstructive disease of the gastrointestinal tract. Caution is also mandatory for patients with hepatic disease, severe heart failure, acute myocardial infarction, hypertension, or epilepsy.

Age and Physiological Status

The medicine is allowed for adults and children aged 6 years and over. It is explicitly not recommended for children under the age of 6 years. Due to the absence of definitive human data and the excretion of the substance in human milk, use during both pregnancy and breastfeeding is officially not advised.

Interactions with other medicines and products

The interaction profile for Reisziekte (Cyclizine) is based predominantly on pharmacodynamic interactions that result in additive effects when combined with certain substance classes.

---

Officially Documented Restrictions

The medicine is contraindicated in the presence of acute alcohol intoxication. Regulatory documents state that the anti-emetic properties of Cyclizine may increase the toxicity of alcohol, and co-administration with alcohol must be avoided entirely.

Interactions with Additive Effects

Co-administration with other Central Nervous System (CNS) Depressants may result in additive effects, increasing the potential for sedation. This category includes substances such as hypnotics, tranquillisers, anaesthetics, antipsychotics, and barbiturates.

Cyclizine may also produce an additive antimuscarinic action with other anticholinergic drugs. This interaction may enhance side-effects when the medicine is combined with agents like tricyclic antidepressants and Monoamine Oxidase Inhibitors ( MAOIs).

Furthermore, the medicine enhances the soporific effect of Opioid Analgesics, specifically Pethidine.

Interaction with Ototoxic Drugs

The drug may mask the warning signs of damage caused by ototoxic drugs, such as aminoglycoside antibacterials. This is a critical interaction-context constraint that obscures a sign of toxicity from the co-administered medicine.

Timing Condition

For the prevention of motion sickness, official labeling requires the medication be taken about one to two hours before departure.

How Reisziekte Works

The compound functions as a competitive antagonist with a high degree of selectivity for muscarinic cholinergic receptors, primarily the M1 and M3 subtypes. This binding interaction occurs within critical components of the central nervous system, specifically the vestibular nuclei and the reticular formation. Antagonism at these sites prevents the binding of the endogenous ligand, acetylcholine.

Inhibition of muscarinic signal transduction reduces the afferent neural excitability originating from the vestibular apparatus. This action modulates the downstream signal cascade involved in integrating sensory inputs related to movement and spatial orientation. Furthermore, the mechanism of action may involve influencing mathrmGABAA receptor-mediated inhibitory neurotransmission. The resulting physiological consequence is the dampening of aberrant signal traffic and the adjustment of excitatory/inhibitory input balance in central processing centers.

Reisziekte (Cyclizine) is administered through the oral route as a 50 mg tablet or via the parenteral route as a 50 mg/mL injection solution, supporting both intramuscular (IM) and intravenous (IV) delivery methods. The administration protocol is structured by age and the form used.

For adults and children over 12 years, the standard single oral dose is 50 mg. This dose may be repeated, but official guidelines restrict the frequency to a maximum of three times daily, mandating a minimum interval of at least 8 hours between doses. The resulting maximum daily adult intake is 150 mg. The tablet form may be taken with or without food. For motion sickness prevention, the initial oral dose is administered one to two hours before the anticipated travel time.

For children aged 6 to 12 years, the standard oral dose is 25 mg. The use of the oral tablet form is officially not recommended for children under 6 years of age.

When administered parenterally, the standard adult IM or IV dose is 50 mg. Specific procedural constraints apply to intravenous use: the solution must be delivered slowly over a period of at least 3 to 5 minutes. It may be diluted with fluids such as Sodium Chloride 0.9% to ensure the required slow rate of administration. Usage duration is typically short-term for acute events, but it may be prescribed for longer courses in specific chronic conditions.

Clinical Research for Motion Sickness

The medical approach to motion sickness (Reisziekte) focuses on counteracting the sensory mismatch between visual input and inner ear balance signals.

Recent clinical trials and reviews have concentrated on the effectiveness and side effect profiles of established and novel pharmacological and behavioral countermeasures.

Pharmacological Agents

Evidence from systematic reviews indicates that several drug classes are associated with a reduced incidence of motion sickness symptoms, particularly when taken before the onset of motion. The two main classes evaluated in large studies are:

• Anticholinergics (e.g., Scopolamine): Generally considered the most effective drug class for prevention, often administered via a transdermal patch for sustained effect. Studies show high preventative efficacy against symptoms like nausea and vomiting.
• First-Generation Antihistamines (e.g., Dimenhydrinate, Meclizine): These agents have also been shown to influence symptom development. A key limitation observed in trials is the common occurrence of side effects, such as drowsiness or sedation, which may impact performance of tasks like driving.

Newer research has explored novel agents, such as neurokinin-1 (NK1) receptor antagonists, which were investigated in randomized, controlled studies for their potential in reducing the incidence of vomiting associated with varied sea conditions.

Non-Pharmacological Strategies

Research confirms that behavioral and environmental adjustments are essential countermeasures. Observed strategies supported by evidence include:

• Visual Focus: Directing the gaze toward a stable visual horizon or a distant stationary point to synchronize visual input with the vestibular system.
• Positioning: Selecting a low-motion location within the vehicle, such as over the wing in an airplane or the front seat of a car.
• Habituation: Repeated, controlled exposure to motion stimuli can result in desensitization over time, an effect that is sometimes compared favorably to drug effectiveness.

Common questions about Reisziekte (FAQ)

Q: What is Reisziekte?

A: Reisziekte is a term used in Dutch meaning travel sickness or motion sickness.

Motion sickness is a common disturbance of the inner ear caused by repeated motion. It occurs when the brain receives conflicting signals about motion and balance from different parts of the body, such as the eyes, inner ears, and sensory nerves.

Q: What are the typical symptoms of motion sickness?

A: Symptoms of motion sickness can vary but commonly include:

• Nausea (feeling sick to your stomach)
• Vomiting
• Dizziness or lightheadedness
• Feeling unwell or generally uncomfortable
• Cold sweats
• Increased salivation

These symptoms can appear quickly when traveling in a car, boat, train, or plane.

Q: What causes motion sickness when traveling?

A: Motion sickness is caused by a mismatch of sensory information perceived by the brain. When you are moving, your inner ear's balance-sensing system (the vestibular system) detects the motion, but your eyes and other parts of your body may send signals to the brain that you are stationary. This confusion leads to the symptoms of motion sickness.

Q: Can motion sickness be treated?

A: Yes, motion sickness can often be prevented or treated with both non-drug and drug options. The specific approach depends on the severity of the symptoms and the type of travel.

• Non-drug methods include focusing on a stable object outside the vehicle, taking control of the vehicle (if possible), or getting fresh air.
• Medications for motion sickness, typically antihistamines or anticholinergics, work by blocking the signals in the brain that trigger nausea and vomiting. These are usually taken before travel.

Consulting a healthcare provider is recommended for personalized advice on treatment.

Q: What is the main class of drug used to treat motion sickness?

A: The main class of over-the-counter drugs used to prevent and treat motion sickness is antihistamines. These include medications like dimenhydrinate or diphenhydramine.

These drugs work by affecting the balancing mechanisms in the inner ear and blocking the brain's signals that cause vomiting. For many people, these are effective, but they can cause side effects like drowsiness.

Q: Is there a non-oral option for preventing severe motion sickness?

A: Yes. For individuals experiencing severe motion sickness, a transdermal patch containing the drug scopolamine (also known as hyoscine) may be prescribed. The patch is typically applied behind the ear and releases the medication slowly over a few days.

This method bypasses the digestive system and can be effective for longer trips, such as on a cruise. It is a prescription-only option in many places and can cause side effects like a dry mouth or blurred vision.

How to Store and Dispose of Reisziekte? (Cyclizine)

Official regulatory labeling defines specific constraints for storing and disposing of this medicine (Cyclizine Hydrochloride).

Required Storage Conditions

The required storage temperature for tablets and capsules is below 30 C (86 F). The product must be stored in its original container to maintain labeled stability.

Child Safety and Handling

Mandatory regulatory requirements state that the medicine must be kept out of the sight and reach of children.

Disposal Requirements

Expired or unused product must be disposed of according to local requirements. The medicine must not be thrown into wastewater or regular household trash. Disposal should occur through an official pharmaceutical take-back scheme or authorized collection point.